Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs BioNano Genomics Inc (BNGO) Price & Performance

REX AI Equity Premium Income ETFTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

REX AI Equity Premium Income ETF vs BioNano Genomics Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.42, while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

AIPIBNGO
Sector
Income / Options OverlayHealth
52-Week High
$44.93$4.92
52-Week Low
$32.45$1.06
Market Cap
$13.66M
Enterprise Value
$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI trades at $37.42, up 0.21% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits a high distribution yield strategy, paying weekly dividends, with recent payouts ranging from $0.23 to $0.26. Support and resistance are tightly clustered around $37-$38, indicating potential volatility. Recent news highlights the fund's transition to weekly distributions and questions about sustainability amid AI market dynamics.

The outlook for AIPI hinges on its ability to sustain high yields through its option-writing strategy, though structural risks and NAV erosion concerns persist. Investment opportunity lies in income generation, but risks include dependency on AI sector performance and capped upside. Analyst sentiment is mixed, with some caution over long-term viability.

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO